Talphera (TLPH) Earnings Date & Reports

Key Takeaways

• Talphera reported a third-quarter 2026 net loss of $4.0 million, or $0.05 per share, narrowing from a $4.4 million loss, or $0.11 per share, a year earlier.
• The per-share loss came in ahead of Wall Street's consensus estimate, marking another quarter in the company's consistent record of beating expectations.
• Cash, cash equivalents, and investments stood at $14.2 million as of September 30, 2026, with roughly $16 million in conditional financing tranches still available.
• Management said the NEPHRO CRRT registrational study has surpassed 75% enrollment but has slowed, prompting a request to the FDA to close enrollment by December 31, 2026.
• The company raised its estimate of peak annual U.S. sales for nafamostat in CRRT to more than $200 million.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages linked here.
• Discover automated strategies and market ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Talphera (NASDAQ: TLPH) is a clinical-stage specialty pharmaceutical company, so its quarterly report is less about product revenue and more about clinical progress, cash runway, and regulatory momentum. The company's lead candidate, Niyad, is an investigational nafamostat-based regional anticoagulant for use during continuous renal replacement therapy (CRRT), a procedure that filters blood for critically ill patients in hospital intensive care units. With no product revenue yet, investors are focused on whether the pivotal NEPHRO CRRT study can finish enrollment, unlock top-line data, and keep the company funded through a potential regulatory submission. Prior quarters showed narrowing losses and steady, if slowing, trial progress, making this report a key checkpoint for the Niyad timeline.

Reported Results

For the third quarter of 2026, Talphera reported a net loss attributable to common shareholders of $4.0 million, or $0.05 per basic and diluted share, compared with a net loss of $4.4 million, or $0.11 per share, in the third quarter of 2025. The result beat the analyst consensus estimate of a larger loss per share, continuing the company's streak of topping expectations.

Revenue was essentially zero, consistent with its pre-commercial stage. Total operating expenses rose to $4.14 million from $3.42 million a year earlier, driven by higher research and development (R&D) expenses of $2.19 million (up from $1.80 million) and selling, general and administrative (SG&A) expenses of $1.95 million (up from $1.62 million). Excluding non-cash stock-based compensation, cash operating expenses totaled $3.8 million, up from $3.3 million in the prior-year period, reflecting increased Niyad development work and pre-launch commercial preparation.

Cash, cash equivalents, and investments were $14.2 million at September 30, 2026. Management reiterated that this balance, combined with roughly $16 million in remaining conditional financing tranches, is expected to fund operations through a potential premarket approval (PMA) decision in 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are tracking a clinical-stage name like Talphera or surveying a broader sector, the AI Screener offers a structured way to surface potential setups and monitor changing conditions.

Market Reaction and Investor Sentiment

Shares reacted positively after the report, with the stock moving higher in after-hours trading as investors focused on the clinical and regulatory updates rather than the headline loss. The narrower-than-expected loss provided a modest positive signal, but the larger drivers of sentiment were management's plan to request an early close to the NEPHRO CRRT study and the upwardly revised market opportunity. Still, sentiment heading into the print had been cautious: the stock had drifted lower since the prior quarter's report and sat near its 200-day moving average, reflecting concerns about enrollment speed and the company's shrinking cash balance. The updated FDA engagement and the raised peak-sales estimate helped address some of those concerns.

Forward Outlook and Key Factors to Monitor

The central question for Talphera going forward is whether the NEPHRO CRRT study can close enrollment on an accelerated basis. Management has requested an FDA "Sprint Meeting" and is seeking agreement to conclude enrollment by December 31, 2026, given that current enrollment already provides more than 80% statistical power for the primary endpoint. FDA feedback is anticipated before year-end.

Top-line data are expected roughly four to six weeks after enrollment closes, which would set up a potential readout in early 2027. That milestone also matters for financing: the two remaining conditional tranches, totaling approximately $16 million, are expected to close around the time of the top-line data release. Investors should therefore watch for clarity on the final patient count, the timing of data, and whether the tranches close as planned.

On the commercial side, the company raised its estimate of peak annual U.S. sales for nafamostat in CRRT to more than $200 million and continues to cite draft KDIGO (Kidney Disease: Improving Global Outcomes) guidelines as supportive. Key factors to monitor include final guideline language, spending discipline against a declining cash balance, and any updates on a potential PMA submission and commercialization strategy.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations